Strategic Collaboration and Financial Backing Propel Olema Pharmaceuticals’ Buy Rating
Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sam ...
The Pharma Letter1d
Novartis deal and $250 million set Olema on the way
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast ...
Novartis and Olema expand alliance with $250m to boost breast cancer trials
Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
Olema, Novartis Partner In Breast Cancer Drug Study; To Place $250 Mln Of Shares; Stock Up
Olema Pharmaceuticals, Inc. (OLMA), a clinical-stage biopharmaceutical company, Monday announced a new clinical trial collaboration ...
Morningstar22d
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “At ENA 2024, we presented three new, robust preclinical data sets. Palazestrant demonstrated combinability and ...
ETF Daily News10d
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up – Still a Buy?
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report)’s share price gapped up prior to trading on Friday .The stock had previously closed at $7.87, but opened at $8.21. Olema ...
Morningstar9d
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the Symposium’s embargo policy. Olema will hold a conference call to discuss these ...
ETF Daily News4d
Analysts Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Price Target at $27.00
Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have been given an average rating of “Buy” by the six brokerages that are covering the company, Marketbeat reports.
Stockhouse2mon
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “At ENA 2024, we presented three new, robust preclinical data sets. Palazestrant demonstrated combinability and enhanced ...
CNN1y
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s ...
The Bakersfield Californian1mon
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the ...